TWA
TVTX icon

TCI Wealth Advisors’s Travere Therapeutics TVTX Stock Holding History

TCI Wealth Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-193
Closed -$4.06K – 2639
2022
Q4 		$4.06K Buy
193
+2
+1% +$42 ﹤0.01% 1665
2022
Q3 		$5K Hold
191
– – ﹤0.01% 1527
2022
Q2 		$5K Hold
191
– – ﹤0.01% 1544
2022
Q1 		$5K Hold
191
– – ﹤0.01% 1603
2021
Q4 		$6K Hold
191
– – ﹤0.01% 1583
2021
Q3 		$5K Buy
+191
New +$3.51K ﹤0.01% 1661
2021
Q2 		– Sell
-69
Closed -$2K – 2457
2021
Q1 		$2K Buy
+69
New +$1.91K ﹤0.01% 1910

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCI Wealth Advisors's TVTX Position: Q1 2023 in Review

TCI Wealth Advisors sold out of Travere Therapeutics (TVTX) in Q1 2023, closing a stake of 193 shares — an estimated $4.06K sold.

TCI Wealth Advisors first reported a position in TVTX in Q1 2021 and held it in 7 quarters. The position peaked at $6K in Q4 2021. 174 funds tracked by Wall St. Rank hold TVTX as of Q1 2023.

  • TCI Wealth Advisors reported no remaining Travere Therapeutics position as of Q1 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 193 Travere Therapeutics shares in Q1 2023, an estimated $4.06K.
  • TCI Wealth Advisors first reported a position in Travere Therapeutics in Q1 2021 and held it in 7 quarters.
  • TCI Wealth Advisors's Travere Therapeutics position peaked at $6K in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2023.

Based on TCI Wealth Advisors's 13F filing for Q1 2023, filed 3 May 2023.